Ethic Inc. Acquires 282 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Ethic Inc. raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 57.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 777 shares of the company’s stock after purchasing an additional 282 shares during the quarter. Ethic Inc.’s holdings in Medpace were worth $258,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of MEDP. Barclays PLC increased its stake in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Medpace by 3.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 21,715 shares of the company’s stock worth $7,214,000 after acquiring an additional 793 shares in the last quarter. Park Avenue Securities LLC grew its stake in shares of Medpace by 39.2% in the 4th quarter. Park Avenue Securities LLC now owns 2,701 shares of the company’s stock worth $897,000 after acquiring an additional 760 shares in the last quarter. Empirical Asset Management LLC bought a new stake in shares of Medpace in the 4th quarter worth $1,032,000. Finally, Merit Financial Group LLC bought a new stake in shares of Medpace in the 4th quarter worth $607,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research note on Monday, March 24th. TD Cowen lowered shares of Medpace from a “buy” rating to a “hold” rating and reduced their target price for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partners assumed coverage on shares of Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price for the company. William Blair reiterated a “market perform” rating on shares of Medpace in a research note on Tuesday, April 22nd. Finally, Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research note on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $349.30.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company’s stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now directly owns 2,998 shares of the company’s stock, valued at $904,856.36. This represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 20.30% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $305.66 on Friday. The company’s 50-day moving average is $304.24 and its 200 day moving average is $327.76. The company has a market capitalization of $8.79 billion, a P/E ratio of 24.20, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the firm earned $3.20 earnings per share. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.